Moderna and Merck melanoma vaccine cuts death or recurrence risk by 42% in phase 3 trial
The mRNA-based personalized cancer vaccine combined with Keytruda reduced the risk of melanoma death or recurrence by 42% in a late-stage trial, though leaked data triggered a sell-off in Moderna shares despite meeting expectations.
